Miglustat capsules

Miglustat capsules

Form: Capsules

Strength: 100 mg

Reference Brands: Zavesca(US)

Category: Orphan Drugs

Miglustat capsules, marketed as Zavesca, are approved in the US by the FDA and in the EU via EMA for treating Gaucher’s disease type 1 and Niemann-Pick disease type C. Regulatory approval requires a detailed dossier including clinical efficacy, safety profiles, manufacturing standards, and pharmacovigilance plans. In the US, the FDA reviews comprehensive clinical trial and quality data for timely approval, while the EMA ensures compliance with regional safety, efficacy, and manufacturing regulations. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper regional adherence supports swift approval, safe use, and worldwide availability, aiding in management of rare metabolic disorders.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Galsulfase IV

Strength: 1mg/ml

Form: Lyophilized powder for IV

Reference Brands: Vimizim®(US & EU)

View Details Get Enquiry
Alglucosidase Alfa IV

Strength: 50 mg/vial

Form: Lyophilized powder

Reference Brands: Lumizyme®(US & EU)

View Details Get Enquiry
Nitisinone tablets

Strength: 2 mg and 5 mg

Form: Tablets

Reference Brands: Orfadin®

View Details Get Enquiry
Treprostinil IV or SC

Strength: 2 mg (0.1 mg/mL), 4 mg (0.2 mg/mL), 8 mg (0.4 mg/mL), 20 mg (1 mg/mL), 50 mg (2.5 mg/mL), 100 mg (5 mg/mL), 200 mg (10 mg/mL), or 400 mg (20 mg/mL)

Form: SC or Intravenous (IV)

Reference Brands: Remodulin®(US & EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.